SCHEMBL6416062

SCHEMBL6416062

O=C(O)c1cccc(C=NNc2nc3nonc3nc2NCc2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.46
LDHA P00338 1/20 0.43
LDHB P07195 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
MAPT P10636 9/20 0.41
KMT2A Q03164 5/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
MEN1 O00255 4/20 0.41
GAA P10253 4/20 0.41
LMNA P02545 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 2/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433093 0.89 GAA (0.45) BIRC5MAPTKMT2ANPC1RAB9A
SCHEMBL6418379 0.87 MAPK1 (0.48) MAPTKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6415963 0.85 BIRC5 (0.52) BIRC5MAPTKMT2ANPC1RAB9A
SCHEMBL6435175 0.84 BIRC5 (0.68) BIRC5LDHAMAPTKMT2ANPC1
SCHEMBL6435171 0.84 BIRC5 (0.68) BIRC5LDHAMAPTKMT2ANPC1
SCHEMBL6414142 0.81 MAPT (0.43) MAPTKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6413667 0.81 DHODH (0.45) MAPTKMT2ARAB9ASMN1; SMN2MEN1
SCHEMBL6432659 0.79 BIRC5 (0.59) BIRC5LDHAMAPTKMT2ANPC1
SCHEMBL6432656 0.79 BIRC5 (0.59) BIRC5LDHAMAPTKMT2ANPC1
SCHEMBL6419258 0.78 PHGDH (0.57) BIRC5LDHAMAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885LDHA 3775/4885LDHB 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.